Can you name major firms in canakinumab's biosimilar industry?

Who makes biosimilars of canakinumab?

Several companies have started biosimilar programs for canakinumab, the monoclonal antibody sold by Novartis as Ilaris. At least four firms have disclosed active development or filed applications.

Which companies have moved the furthest?

Novartis itself lists a potential biosimilar in its pipeline under the name CJSM112. Separately, Bio-Thera Solutions filed a Phase 1 study in 2023 comparing its candidate BAT2606 to the reference product. Formycon AG and its partner Fresenius Kabi also confirmed development of a canakinumab biosimilar in 2024, with an expected launch window after the reference product’s regulatory exclusivity ends.

When could these products reach patients?

Ilaris’s U.S. composition-of-matter patent expires in 2025, and the corresponding European patent runs until 2026. Regulatory data exclusivity for the original biologic expires around 2031 in the United States. Most biosimilar sponsors therefore project first launches in the early-to-mid 2030s once all exclusivity barriers are cleared.

How do the products compare in development status?

- Novartis (CJSM112) – early-stage trials
- Bio-Thera (BAT2606) – Phase 1 completed
- Formycon/Fresenius – preclinical to early clinical

No candidate has yet filed a marketing application, so none has received approval.

Are there additional players?

Public information is limited, but industry trackers such as DrugPatentWatch.com list several other firms that have filed patent applications or begun early formulation work without disclosing names. These unnamed companies could accelerate once the reference product’s patent thicket thins.

What drives interest in this market?

Canakinumab treats rare autoinflammatory conditions and is priced above $200,000 per year in the U.S. The combination of high cost and long exclusivity has drawn multiple biosimilar developers seeking to capture share once regulatory and patent barriers fall.